News

At the American Academy of Dermatology 2026 meeting, dermatology leaders emphasized the growing need for advocacy to address rural access disparities and the escalating impact of climate change on patient care and health systems.

Litifilimab, a monoclonal antibody that reduces type-I interferon production and inflammation, has the potential to be a first-in-class targeted therapy for patients with cutaneous lupus.

Barbieri, director of the Advanced Acne Therapeutics Clinic at Brigham and Women's Hospital in Boston, discusses the complexities of figuring out cost-effect acne treatment.

The 2026 American Academy of Dermatology meeting began today in Denver, featuring a keynote conversation this evening with John Legend on wellness, identity and his Loved01 skincare brand.

Studies have shown that routine monitoring for hyperkalemia has limited usefulness, says Barbieri, director of the Advanced Acne Therapeutics Clinic at Brigham and Women's Hospital in Boston.

Barbieri, director of the Advanced Acne Therapeutics Clinic at Brigham and Women's Hospital in Boston, provided an update on spironolactone at the American Academy of Dermatology meeting in Denver.

CEO of Veradermics, Reid Waldman, M.D., shared that faster hair growth and shifting patient views on prescription treatments could play a key role in improving adherence and outcomes for pattern hair loss.

Vitiligo is a chronic autoimmune disease that affects skin pigmentation and, while not painful or contagious, requires greater attention in managed care due to its long-term nature and psychosocial impact.

Nearly half of patients skip care when costs are unclear. Although price estimates are improving, affordability and financial anxiety remain major barriers to accessing healthcare.

A new JAMA study compares the U.S. and South Korea, revealing sharper income-driven gaps in access, spending and outcomes, and why policy fixes matter.

In a "low mitigation" scenario, work requirements and redetermination every six months would mean a 55% decline in projected 2028 Medicaid enrollment, from 18.4 million to 8.3 million.

Results of a study done at Cedars-Sinai Medical Center in Los Angeles and Brigham and Women's Hospital in Boston suggest that older patients with low medication adherence and literacy might benefit from a pharmacist-led medication management as they are leaving the hospital.

Jefferson health and Ipendence Blue Cross are working together to improve early dementia detection and care coordination in primary care, helping patients receive support sooner and stay healthier at home

Eli Lilly's once-daily oral GLP-1, orforglipron, awaits FDA approval in April 2026. New research shows orforglipron outperforms oral semaglutide for lowering A1C and for weight loss.

Pharmacists have the training and are employed by the health system so it makes sense to put them in charge of postdischarge medication planning and management

Joshua M. Pevnick, M.D., M.S.H.S., discusses medications and the risk of an adverse drug event among older people after they get discharged from the hospital.

A childhood teacher once told Rachel Moseley, Ph.D., there was “no point” in teaching her math. Since then, she has graduated from Cambridge University in England with a doctorate in cognitive neuroscience. She and a colleague have recently published a book of interviews exploring menopause among people with autism.

UnitedHealthcare is expanding access to doula services through eligible employer-sponsored plans, aiming to improve maternal health outcomes and provide more comprehensive pregnancy support.

This FAQ outlines what managed care leaders need to know about emerging oral GLP-1 therapies, including their clinical uses, growing demand and potential impact on healthcare costs and coverage.

More than half of people in a recent survey said they find it difficult to find the lowest-cost option for their medications, and they don’t trust that they are paying the lowest price.

Chronic back pain amplifies sound unpleasantness; fMRI links it to sensory circuits, and pain reprocessing therapy may help normalize responses.

Lynavoy is used to treat cholestatic pruritus, an extreme itch that affects almost 90% of patients with primary biliary cholangitis.

Findings published In JAMA Oncolog sound a note of caution about repurposing drugs for one type of cancer to another based on biomarkers alone.

In this conversation, Kirk Grisham, M.P.H., and Vishakh Unnikrishnan, M.P.H., both from the Center for HIV and Infectious Disease Policy at the O’Neill Institute, explain how federal funding cuts are destabilizing state HIV programs and why state leadership and political will now largely determine whether people keep access to HIV prevention and care.

CLDN18.2-high gastroesophageal cancer appears more common and could predict a stronger HER2 therapy benefit but a weaker immunotherapy response.